Zeria Pharmaceutical Management
Management criteria checks 2/4
Zeria Pharmaceutical's CEO is Sachiaki Ibe, appointed in Jun 2014, has a tenure of 10.75 years. directly owns 3.61% of the company’s shares, worth ¥3.64B. The average tenure of the management team and the board of directors is 2.8 years and 6.7 years respectively.
Key information
Sachiaki Ibe
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 10.8yrs |
| CEO ownership | 3.6% |
| Management average tenure | 2.8yrs |
| Board average tenure | 6.7yrs |
Recent management updates
Recent updates
Zeria Pharmaceutical's (TSE:4559) Dividend Will Be ¥23.00
Feb 24
Zeria Pharmaceutical (TSE:4559) Is Due To Pay A Dividend Of ¥23.00
Feb 10Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥23.00
Jan 17Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥23.00
Jan 03Zeria Pharmaceutical (TSE:4559) Is Due To Pay A Dividend Of ¥23.00
Dec 17Zeria Pharmaceutical (TSE:4559) Will Pay A Dividend Of ¥23.00
Dec 03Zeria Pharmaceutical's (TSE:4559) Earnings Are Of Questionable Quality
May 21Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥22.00
Mar 15CEO
Sachiaki Ibe (83 yo)
10.8yrs
Tenure
Mr. Sachiaki Ibe serves as the Chief Executive Officer and Chairman at Zeria Pharmaceutical Co., Ltd since June 2014 and served as its President since April 1982. Mr. Ibe served as Managing Director of Zer...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 10.8yrs | no data | 3.61% ¥ 3.6b | |
| President | 10.8yrs | no data | 0.19% ¥ 189.7m | |
| Executive Officer and GM of Finance & Accounting Division | no data | no data | no data | |
| Executive Officer and GM of Research & Development Headquarters | 11.8yrs | no data | no data | |
| Managing Executive Officer and GM of Asian Business | 2.8yrs | no data | no data | |
| Executive Officer and GM of Reliability Assurance Headquarters & Customer Relations Office | no data | no data | no data | |
| Executive Officer & GM of Consumer Healthcare Sales Division | 2.8yrs | no data | no data | |
| Managing Executive Officer & Director | 2.8yrs | no data | 0.023% ¥ 22.9m | |
| Executive Officer & GM of Production & Logistics Headquarters | 2.8yrs | no data | no data | |
| Executive Officer & GM of Pharmaceutical Sales Division | 2.8yrs | no data | no data | |
| Executive Officer and GM of Corporate Planning Division & Corporate Strategy Promotion Division | 2.5yrs | no data | no data | |
| Executive Officer & Head of European Business Headquarters | 2.2yrs | no data | no data |
2.8yrs
Average Tenure
61yo
Average Age
Experienced Management: 4559's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 53yrs | no data | 3.61% ¥ 3.6b | |
| President | 14.8yrs | no data | 0.19% ¥ 189.7m | |
| Managing Executive Officer & Director | 1.8yrs | no data | 0.023% ¥ 22.9m | |
| Independent External Director | 9.8yrs | no data | 0.016% ¥ 16.0m | |
| Full-Time Audit & Supervisory Board Member | 1.8yrs | no data | 0.18% ¥ 182.8m | |
| Outside Audit & Supervisory Board Member | 21.8yrs | no data | 0.016% ¥ 16.0m | |
| Independent External Director | 7.7yrs | no data | no data | |
| Outside Audit & Supervisory Board Member | 5.8yrs | no data | 0.0023% ¥ 2.3m | |
| Independent External Director | 4.8yrs | no data | 0.0023% ¥ 2.3m | |
| Full-time Audit & Supervisory Board Member | less than a year | no data | 0.0023% ¥ 2.3m |
6.7yrs
Average Tenure
65yo
Average Age
Experienced Board: 4559's board of directors are considered experienced (6.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 22:47 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zeria Pharmaceutical Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Takashi Akahane | Tokai Tokyo Intelligence Laboratory Co., Ltd. |
| Jayaprabha Dhavale | Virtua Research Inc. |